Trial Profile
A phase II study assessing tumor blood flow as measured by dynamic contrast enhanced MRI [magnetic resonance imaging] in patients with metastatic colorectal cancer receiving FOLFOX [calcium folinate + fluorouracil + oxaliplatin] alone versus patients randomized to receive FOLFOX plus bevacizumab at 5mg/kg or 10mg/kg
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 24 Apr 2020 Status changed from completed to discontinued.
- 12 Apr 2019 Status changed from recruiting to completed.
- 25 Feb 2008 New trial record.